Meet Sapna Patel, M.D.
Sapna Patel, B.A., M.D.
Department of Melanoma Medical Oncology, Division of Cancer Medicine
About Dr. Patel
Dr. Patel is a medical oncologist and Associate Professor, Director of the Uveal Melanoma Program, and Melanoma Fellowship Program Director at the University of Texas MD Anderson Cancer Center in Houston, Texas specializing in uveal, cutaneous, and mucosal melanoma with one of the largest metastatic uveal melanoma practices in the world. She has led several investigator-initiated and multi-institutional clinical trials, including studies of targeted therapy, immunotherapy, T cell therapy, and antibody-drug conjugates for uveal melanoma. Her lab work focuses on translational research, characterizing longitudinal molecular signatures in tumor samples from patients receiving treatment. She also leads several cutaneous melanoma projects with SWOG and serves as Melanoma Chair for SWOG. She has received intramural and extramural funding including NIH grants. Her goal is to develop effective therapies for adjuvant and metastatic settings, and to identify biomarkers to predict clinical benefit.
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX
Chair, Melanoma Committee, Southwest Oncology Group (SWOG), San Antonio, TX
Uveal Melanoma Program Director, Department of Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX
Fellowship Program Director, Department of Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2005 | The University of Texas Medical Branch, Galveston, TX, USA, MD, Medicine |
| 2000 | The University of Texas at Austin, Austin, TX, USA, BA, Microbiology |
Postgraduate Training
| 2008-2011 | Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 2006-2008 | Clinical Residency, Internal Medicine, The University of Colorado at Denver and Health Sciences Center, Denver, CO |
| 2005-2006 | Clinical Internship, Internal Medicine, The University of Colorado at Denver and Health Science Center, Denver, CO |
Board Certifications
| 2011 | American Board of Internal Medicine, Medical Oncology |
| 2008 | American Board of Internal Medicine |
Experience & Service
Administrative Appointments/Responsibilities
Division of Cancer Medicine Representative, PRS Executive Council, Houston, TX, 2016 - 2022
Fellowship Director of Moonlighting, Department of Hematology/Oncology, MD Anderson Cancer Center, Houston, TX, 2010 - 2011
Other Appointments/Responsibilities
Podcast Host, MD Anderson Cancer Newsline, Houston, TX, 2016 - Present
Faculty Consultant, MD Anderson Physician Network, Houston, TX, 2014 - 2016
Faculty Senator, MD Anderson Cancer Center, Houston, TX, 2014 - 2022
Editorial Board, OncoLog, Houston, TX, 2012 - Present
Institutional Committee Activities
Member, Institutional Review Board 5, 2019 - Present
Member, Pharmacy and Therapeutics Committee, 2014 - Present
Member, Hematology/Oncology Fellowship Steering Committee, 2014 - 2020
Member, Graduate Medical Education Committee, 2014 - Present
Associate Member, Institutional Review Board 5, 2013 - Present
Member, Clinical Research Committee 3, 2013 - 2015
Member, Investigational New Drug Committee, 2013 - Present
Ambassador, Champion, Super User, and Officer, EPIC OneConnect, 2013 - Present
Member, ICD-10 Provider Ambassador, 2013 - Present
Member, Clinical Research Committee 3, 2011 - 2012
Consultantships
Medical Advisory Board, A Cure in Sight, Houston, TX, 2016 - Present
Reviewer, The Medical Letter, New Rochelle, NY, 2011 - 2011
Military or Other Governmental Service
Special Government Employee, US Food and Drug Administration, 2013 - 2018
Honors & Awards
| 2022 | Finalist, Gerald P. Bodey Award for Excellence in Education, MD Anderson Cancer Center |
| 2021 | PRIME funding, MD Anderson Cancer Center |
| 2016 | NCI / CTEP Career Development Award for Proposal 9855 |
| 2014 | MD Anderson High Impact Clinical Research Support Program Funding, MD Anderson |
| 2012 | MD Anderson High Impact Clinical Research Support Program Funding |
| 2010 | Allison and Brian Grove Endowed Fellowship for Breast Medical Oncology, MD Anderson |
| 2010 | ASCO Cancer Foundation Merit Award, ASCO Annual Meeting |
| 2010 | ASCO Cancer Foundation Merit Award, ASCO-NCI-EORTC Molecular Markers in Cancer |
| 2009 | Young Investigator Award, Ocular Melanoma Foundation |
| 2006 | 2nd Place, Rocky Mountain Hospitalist Symposium Abstract Competition |
| 2006 | 2nd Place, Biosymposia Signaling Transduction Modulators in Cancer Therapy Symposium |
| 2006 | Finalist, Humanism and Excellence in Teaching, The University of Colorado at Denver and Health Sciences Center School of Medicine |
| 1999 | College of Natural Sciences Honor List, The University of Texas at Austin |
| 1999 | College Scholar, The University of Texas at Austin |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Khan S, Patel SP, Shoushtari AN, Ambrosini G, Cremers S, Lee S, Franks L, Singh-Kandah S, Hernandez S, Sender N, Vuolo K, Nesson A, Mundi P, Izar B, Schwartz GK, Carvajal RD. Intermittent MEK inhibition for the treatment of metastatic uveal melanoma. Front Oncol 12:975643, 2022. e-Pub 2022. PMID: 36249046.
- Patel SP, Kim DW, Bassett RL, Cain S, Washington E, Hwu WJ, Kim KB, Papadopoulos NE, Homsi J, Hwu P, Bedikian AY. A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma. Cancer Immunol Immunother 66(10):1359-1366, 2017. e-Pub 2017. PMID: 28612140.
- Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, De Macedo MP, Chen E, Austin-Breneman JL, Jiang H, Roszik J, Tetzlaff MT, Davies MA, Gershenwald JE, Tawbi H, Lazar AJ, Hwu P, Hwu WJ, Diab A, Glitza IC, Patel SP, Woodman SE, Amaria RN, Prieto VG, Hu J, Sharma P, Allison JP, Chin L, Zhang J, Wargo JA, Futreal PA. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med 9(379), 2017. PMID: 28251903.
- Clark JI, Wong MK, Kaufman HL, Daniels GA, Morse MA, McDermott DF, Agarwala SS, Lewis LD, Stewart JH, Vaishampayan U, Curti B, Gonzalez R, Lutzky J, Rudraptna V, Cranmer LD, Jeter JM, Hauke RJ, Miletello G, Milhem MM, Amin A, Richart JM, Fishman M, Hallmeyer S, Patel SP, Van Veldhuizen P, Agarwal N, Taback B, Treisman JS, Ernstoff MS, Perritt JC, Hua H, Rao TB, Dutcher JP, Aung S. Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM. Clin Genitourin Cancer 15(1):31-41, 2017. PMID: 27916626.
- Qin Y, Petaccia de Macedo M, Reuben A, Forget MA, Haymaker C, Bernatchez C, Spencer CN, Gopalakrishnan V, Reddy S, Cooper ZA, Fulbright OJ, Ramachandran R, Wahl A, Flores E, Thorsen ST, Tavera RJ, Conrad C, Williams MD, Tetzlaff MT, Wang WL, Gombos DS, Esmaeli B, Amaria RN, Hwu P, Wargo JA, Lazar AJ, Patel SP. Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: a pilot study. Oncoimmunology 6(6):e1321187, 2017. e-Pub 2017. PMID: 28680759.
- Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K, Chen E, Haymaker C, Forget MA, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, Davies MA, Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JA. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med, 2017. PMID: 28819565.
- McQuade JL, Posada LP, Lecagoonporn S, Cain S, Bassett RL, Patel SP, Hwu WJ, Hwu P, Davies MA, Bedikian AY, Amaria RN. A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma. Melanoma Res 26(6):604-608, 2016. e-Pub 2016. PMID: 27540836.
- Chen G, McQuade JL, Panka DJ, Hudgens CW, Amin-Mansour A, Mu XJ, Bahl S, Jané-Valbuena J, Wani KM, Reuben A, Creasy CA, Jiang H, Cooper ZA, Roszik J, Bassett RL, Joon AY, Simpson LM, Mouton RD, Glitza IC, Patel SP, Hwu WJ, Amaria RN, Diab A, Hwu P, Lazar AJ, Wargo JA, Garraway LA, Tetzlaff MT, Sullivan RJ, Kim KB, Davies MA. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. JAMA Oncol 2(8):1056-64, 2016. PMID: 27124486.
- Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov 6(8):827-37, 2016. e-Pub 2016. PMID: 27301722.
- Johnson DB, Roszik J, Shoushtari AN, Eroglu Z, Balko JM, Higham C, Puzanov I, Patel SP, Sosman JA, Woodman SE. Comparative analysis of the GNAQ, GNA11, SF3B1, and EIF1AX driver mutations in melanoma and across the cancer spectrum. Pigment Cell Melanoma Res 29(4):470-3, 2016. PMID: 27089234.
- Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, Woodman SE, Glitza IC, Diab A, Vence LM, Rodriguez-Canales J, Parra ER, Wistuba II, Coussens LM, Sharpe AH, Flaherty KT, Gershenwald JE, Chin L, Davies MA, Clise-Dwyer K, Allison JP, Sharma P, Wargo JA. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology 5(3):e1136044, 2016. e-Pub 2016. PMID: 27141370.
- Patel SP, Kim DW, Lacey CL, Hwu P. GNA11 Mutation in a Patient With Cutaneous Origin Melanoma: A Case Report. Medicine (Baltimore) 95(4):e2336, 2016. PMID: 26825879.
- Buchbinder EI, Gunturi A, Perritt J, Dutcher J, Aung S, Kaufman HL, Ernstoff MS, Miletello GP, Curti BD, Daniels GA, Patel SP, Kirkwood JM, Hallmeyer S, Clark JI, Gonzalez R, Richart JM, Lutzky J, Morse MA, Sullivan RJ, McDermott DF. A retrospective analysis of High-Dose Interleukin-2 (HD-IL-2) following Ipilimumab in metsatatic melanoma. J Immunother Cancer, 2016. PMID: 27660706.
- Janku F, Huang HJ, Claes B, Falchook GS, Fu S, Hong D, Ramzanali NM, Nitti G, Cabrilo G, Tsimberidou AM, Naing A, Piha-Paul SA, Wheler JJ, Karp DD, Holley VR, Zinner RG, Subbiah V, Luthra R, Kopetz S, Overman MJ, Kee BK, Patel S, Devogelaere B, Sablon E, Maertens G, Mills GB, Kurzrock R, Meric-Bernstam F. BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. Mol Cancer Ther 15(6):1397-404, 2016. PMID: 27207774.
- Glitza IC, Haymaker C, Bernatchez C, Vence L, Rohlfs M, Richard J, Lacey C, Mansaray R, Fulbright OJ, Ramachandran R, Toth C, Wardell S, Patel SP, Woodman SE, Hwu WJ, Radvanyi LG, Davies MA, Papadopoulos NE, Hwu P. Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report. Cancer Immunol Res 3(11):1201-6, 2015. e-Pub 2015. PMID: 26216417.
- Janku F, Claes B, Huang HJ, Falchook GS, Devogelaere B, Kockx M, Bempt IV, Reijans M, Naing A, Fu S, Piha-Paul SA, Hong DS, Holley VR, Tsimberidou AM, Stepanek VM, Patel SP, Kopetz ES, Subbiah V, Wheler JJ, Zinner RG, Karp DD, Luthra R, Roy-Chowdhuri S, Sablon E, Meric-Bernstam F, Maertens G, Kurzrock R. BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget 6(29):26886-94, 2015. e-Pub 2015. PMID: 26330075.
- Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, Haydu L, Prieto VG, Tetzlaff M, Ivan D, Wang WL, Torres-Cabala C, Curry J, Roy-Chowdhuri S, Broaddus R, Rashid A, Stewart J, Gershenwald JE, Amaria RN, Patel SP, Papadopoulos NE, Bedikian A, Hwu WJ, Hwu P, Diab A, Woodman SE, Aldape KD, Luthra R, Patel KP, Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F, Kim KB, Routbort MJ, Lazar AJ, Davies MA. Beyond BRAF(V600): Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma. J Invest Dermatol 135(2):508-15, 2015. e-Pub 2014. PMID: 25148578.
- Alrwas A, Papadopoulos NE, Cain S, Patel SP, Kim KB, Deburr TL, Bassett R, Hwu WJ, Bedikian AY, Davies MA, Woodman SE, Hwu P. Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic melanoma. Melanoma Res 24(4):342-8, 2014. PMID: 24743052.
- Kim CY, Kim DW, Kim K, Curry J, Torres-Cabala C, Patel S. GNAQ mutation in a patient with metastatic mucosal melanoma. BMC Cancer 14:516, 2014. e-Pub 2014. PMID: 25030020.
- Kolandjian NA, Wei C, Patel SP, Richard JL, Dett T, Papadopoulos NE, Bedikian AY. Delayed Systemic Recurrence of Uveal Melanoma. Am J Clin Oncol 36(5):443-9, 2013. e-Pub 2012. PMID: 22706174.
- Vence LM, Wang C, Pappu H, Anson RE, Patel TA, Miller P, Bassett R, Lizee G, Overwijk WW, Komanduri K, Benjamin C, Alvarado G, Patel SP, Kim K, Papadopoulos NE, Bedikian AY, Homsi J, Hwu WJ, Boyd R, Radvanyi L, Hwu P. Chemical castration of melanoma patients does not increase the frequency of tumor-specific CD4 and CD8 T cells after peptide vaccination. J Immunother 36(4):276-86, 2013. PMID: 23603862.
- Patel SP, Lazar AJ, Papadopoulos NE, Liu P, Infante JR, Glass MR, Vaughn CS, LoRusso PM, Cohen RB, Davies MA, Kim KB. Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma. Cancer 119(4):799-805, 2013. e-Pub 2012. PMID: 22972589.
- Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, Wu R, Lizee G, Mahoney S, Alvarado G, Glass M, Johnson VE, McMannis JD, Shpall E, Prieto V, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Patel S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Davies MA, Mansaray R, Fulbright OJ, Toth C, Ramachandran R, Wardell S, Gonzalez A, Hwu P. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 18(24):6758-70, 2012. e-Pub 2012. PMID: 23032743.
- Kim J, Lazar AJ, Davies MA, Homsi J, Papadopoulos NE, Hwu WJ, Bedikian AY, Woodman SE, Patel SP, Hwu P, Kim KB. BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma. J Cutan Pathol 39(9):821-5, 2012. e-Pub 2012. PMID: 22809251.
- Alvarado G, Noor R, Bassett R, Papadopoulos NE, Kim KB, Hwu WJ, Bedikian A, Patel S, Hwu P, Davies MA. Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases. Melanoma Res 22(4):310-5, 2012. e-Pub 2012. PMID: 22584956.
- Patel SP, Kim KB, Papadopoulos NE, Hwu WJ, Hwu P, Prieto VG, Bar-Eli M, Zigler M, Dobroff A, Bronstein Y, Bassett RL, Vardeleon AG, Bedikian AY. A phase II study of gefitinib in patients with metastatic melanoma. Melanoma Res 21(4):357-63, 2011. PMID: 21738104.
- Kolandjian NA, Patel SP, Papadopoulos NE, Bedikian AY. The left ventricle as the first site of uveal melanoma metastasis 13 years after treatment of the primary tumor. Melanoma Res 21(2):160-3, 2011. PMID: 21346640.
Invited Articles
- Chattopadhyay C, Kim DW, Gombos DS, Oba J, Qin Y, Williams MD, Esmaeli B, Grimm EA, Wargo JA, Woodman SE, Patel SP. Uveal melanoma: From diagnosis to treatment and the science in between. Cancer 122(15):2299-312, 2016. e-Pub 2016. PMID: 26991400.
- Kim DW, Anderson JE, Patel SP. Immunotherapy for Uveal Melanoma. Melanoma Management 3(2):125-135, 2016. PMID: 30190881.
- Kim DW, Patel SP. Profile of selumetinib and its potential in the treatment of melanoma. Onco Targets Ther 7:1631-9, 2014. e-Pub 2014. PMID: 25278770.
- Patel SP. Latest developments in the biology and management of uveal melanoma. Curr Oncol Rep 15(6):509-16, 2013. PMID: 24122445.
- Patel SP, Kim KB. Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma. Expert Opin Investig Drugs 21(4):531-9, 2012. e-Pub 2012. PMID: 22394161.
- Patel SP, Woodman SE. Profile of ipilimumab and its role in the treatment of metastatic melanoma. Drug Des Devel Ther 2011(5):489-495, 2011. e-Pub 2011. PMID: 22267918.
- Trinh VA, Patel SP, Hwu WJ. The safety of temozolomide in the treatment of malignancies. Expert Opin Drug Saf 8(4):493-9, 2009. PMID: 19435405.
Book Chapters
- Kim DW, Gershenwald JE, Patel SP, Davies MA. Ch. 41: Melanoma. In: The MD Anderson Manual of Medical Oncology. 3rd ed. McGraw-Hill: New York, 857-873, 2016.
- Bashour, SI, William WN, Patel S, Rao G, Strom E, McAleer MF, Guha-Thakurta N, Conrad C, Ibrahim NK. Ch 1 - Brain Metastasis from Solid Tumors. In: Brain Metastases from Primary Tumors. 1. Academic Press: San Diego, 3-29, 2015.
- Francis JH, Patel SP, Gombos DS, Carvajal RD. Surveillance options for patients with uveal melanoma following definitive management. In: Am Soc Clin Oncol Educ Book, 382-7, 2013.
- Patel SP, Gombos DS. Ch 12: Adjunctive treatment strategies for high-risk ocular melanoma. In: Ocular Melanoma: Advances in Diagnostic and Therapeutic Strategies. Future Science Group: UK, 160-167, 2013.
- Chae YK, Patel SP, Kim KB. Emerging Targets for Melanoma Therapy Besides BRAF. In: Emerging Cancer Theraputics: Melanoma. Demos Medical Publishing LLC: New York, NY, 2012.
- Joseph RW, Kim K, Patel SP. Ch. 27: Role of Chemotherapy, biochemotherapy, and targeted systemic therapies in the treatment of melanoma. In: Cutaneous Malignancy of the Head and Neck: A Multidisciplinary Approach. Plural Publishing: San Diego, CA, 2011.
- Patel SP, Buzdar AU. Ch.24: Early and locally advanced breast cancer. In: MD Anderson Manual of Medical Oncology. 2nd ed. McGraw-Hill: New York, 2011.
Letters to the Editor
- Patel S. It's Right, Left is Rare 97: 1482-3, 2014.
Grant & Contract Support
| Title: | High-dose interleukin-2 video series |
| Funding Source: | Volunteer Endowment for Patient Support (VEPS) |
| Role: | Project Leader |
| Title: | An open label, multicenter, dose-escalation, phase 1b/2 study of the safety, efficacy, pharmacodynamics and pharmacokinetics of RTA 408 in combination with ipilimumab in the treatment of patients with unresectable of metastatic melanoma |
| Funding Source: | REATA PHARMACEUTICALS INC |
| Role: | Principal Investigator-MDACC |
| Title: | Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High-Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma |
| Funding Source: | Prometheus Therapeutics INC |
| Role: | Principal Investigator-MDACC |
| Title: | Expanded Access Program with Nivolumab (BMS-396558) with Ipilimumab (Yervoy) in Anti-CTLA-4 Treatment Naive Subjects with Unresectable or Metastatic Melanoma |
| Funding Source: | Bristol-Myers Squibb |
| Role: | Principal Investigator-MDACC |
| Title: | Long Peptide Vaccine with TLR Agonist Study |
| Funding Source: | Melanoma Research Alliance/University of Virginia |
| Role: | Principal Investigator-MDACC |
| Title: | BRAF inhibitor Dabrafenib +/- MEK inhibitor Trametinib in combination with ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma |
| Funding Source: | GSK Biologicals |
| Role: | Principal Investigator-MDACC |
| Title: | Phase II study of nivolumab in combination with ipilimumab for uveal melanoma |
| Funding Source: | Bristol-Myers Squibb |
| Role: | Principal Investigator-MDACC |
| Title: | A Phase 3 Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab versus ipilimumab Monotherapy in subjects with previously untreated unresectable or Metastatic Melanoma |
| Funding Source: | Bristol-Myers Squibb |
| Role: | Principal Investigator-MDACC |
| Title: | AN OPEN-LABEL, MULTICENTER, PHASE III TRIAL OF ABI-007 V |
| Funding Source: | ABRAXIS BIOSCIENCE LLC |
| Role: | Principal Investigator-MDACC |
| Title: | An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the BRAF Inhibitor GSK2118436 in Combination with the MEK Inhibitor GSK1120212 in Subjects with BRAF Mutant Metastatic Melanoma |
| Funding Source: | GlaxoSmithKline |
| Role: | Principal Investigator-MDACC |
| Title: | A Phase Ib/II multicenter open-label dose escalation study of LGX818 in combination with MEK162 in adult patients with BRAF V600 dependent advanced solid tumors |
| Funding Source: | Novartis |
| Role: | Principal Investigator-MDACC |
| Title: | PROCLAIM:Proleukin Observation Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy |
| Funding Source: | PROMETHEUS THERAPEUTICS INC |
| Role: | Principal Investigator-MDACC |
| Title: | Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MED14736 in Subjects with Advanced Solid Tumors (2012-0513) |
| Funding Source: | MedImmune LLC (Cohort B) |
| Role: | Principal Investigator-MDACC |
| Title: | Unlocking Tumor Immunophenotype in Responders versus Non-Responders in Metastatic Uveal Melanoma Patients Receiving Immune Checkpoint Blockade |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | S1404 - SWOG - A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients with High risk Resected Melanoma |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator-MDACC |
| Title: | NCI9855 - NCI - Southwest Early Clinical Trials Consortium - Project 2 |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | Exploring Differential Immunophenotypes in Uveal Melanoma and their Relationship to Treatment Response |
| Funding Source: | MD Anderson Institutional Research Grant |
| Role: | Principal Investigator |
| Title: | Characterizing Metastasis-Competent Circulating Tumor Cells from Uveal Melanoma Patients |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | Developing Effective Immunotherapeutic Strategies for Advanced Uveal Melanoma |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-Principal Investigator |
| Title: | Multi-Center Phase IB Study of Intermittent Dosing of the MEK inhibitor, Selumetinib, in Patients with advanced Uveal Melanoma Not Previously Treated with a MEK Inhibitor |
| Funding Source: | Melanoma Research Alliance Team Science Award |
| Role: | Principal Investigator |
| Title: | Phase II single-arm multi-center study of adjuvant ipilimumab in combination with nivolumab in subjects with high-risk ocular melanoma |
| Funding Source: | Hoosier Cancer Research Network |
| Role: | Principal Investigator-MDACC |
| Title: | A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of PV-10 Chemoablation of Cancer Metastatic to the Liver or Hepatocellular Carcinoma not Amenable to Resection or Transplant |
| Funding Source: | Provectus Pharmaceuticals Inc |
| Role: | Principal Investigator-MDACC |
| Title: | A Phase 3 Randomized Study of Adjuvant Immunotherapy with Nivolumab Combined with Ipilimumab Versus Nivolumab Monotherapy after Complete Resection of Stage IIIb/c/d or Stage IV Melanoma |
| Funding Source: | Bristol-Myers Squibb |
| Role: | Principal Investigator-MDACC |
| Title: | Evaluation of Intermittent MEK Inhibition in Uveal Melanoma |
| Funding Source: | The Trustees of Columbia University |
| Role: | Principal Investigator-MDACC |
| Title: | Immunotherapeutic Targeting of SLC45A2 for Treatment of Uveal Melanoma |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-Principal Investigator |
| Title: | Project 3: Immunotherapeutic Targeting of SLC45A2 for Treatment of Uveal Melanoma |
| Funding Source: | NIH/NCI |
| Role: | Project Co-Leader |
| Title: | Integration of liquid biopsy and microbiome analysis as biomarkers for clinical outcome in uveal melanoma |
| Funding Source: | MD Anderson Cancer Center Bridge Funding |
| Role: | Principal Investigator |